Novartis used a priority review voucher for brolucizumab, positioning the eye drug for a US launch in late 2019 if the FDA review goes smoothly.

Drug makers and other stakeholders have been rolling out insulin savings programs as the high cost of insulins come under scrutiny on Capitol Hill. Sanofi announced an expanded cost-savings program during a House hearing, but one Congresswoman called them a band-aid. 

Drug makers remained front and center during the Senate Finance Committee's third hearing on drug pricing, even though leaders from five pharmacy benefit managers were testifying.

Drug makers remained front and center during the Senate Finance Committee's third hearing on drug pricing, even though leaders from five pharmacy benefit managers were testifying.

Bernstein Research analysts said CMS could charge pharmaceutical manufactures a fee to offset increases in insurance premiums anticipated from the elimination of rebates in a "win-win" move.

Bernstein Research analysts said CMS could charge pharmaceutical manufactures a fee to offset increases in insurance premiums anticipated from the elimination of rebates in a "win-win" move.